Hunter Syndrome Treatment Market To Reach $2.15 Billion by 2035

Hunter syndrome treatment market was valued at $1.07 billion in 2025 and is projected to reach $2.15 billion by 2035, growing at a CAGR of 7.23% during the forecast period (2026–2035). The increasing prevalence of rare genetic disorders and rising focus on orphan drug development are key macro drivers supporting market growth. According to the World Health Organization, rare diseases affect approximately 400 million people globally, highlighting the significant unmet need for specialized treatments. Hunter syndrome (MPS II), a rare lysosomal storage disorder, requires long-term therapeutic intervention such as enzyme replacement therapy and gene therapy. Increasing regulatory support for orphan drugs and advancements in biotechnology are accelerating the development and commercialization of innovative treatment options.

Browse the full report description of “Hunter Syndrome Treatment Market Size, Share & Trends Analysis Report, By Treatment Type (Enzyme Replacement Therapy (ERT), Gene Therapy, Substrate Reduction Therapy (SRT), Supportive / Symptomatic Treatment), By End-User (Hospitals, Specialty Clinics, Homecare Settings), By Therapy Modality (Biologics, Gene Therapy Platforms, Small Molecule Therapies), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/hunter-syndrome-treatment-market

Rising Biopharmaceutical Innovation Driving Market Growth

Advancements in biologics and gene therapy platforms are significantly influencing the Hunter syndrome treatment market. According to the U.S. Food and Drug Administration, over 1,000 orphan drug designations are granted annually, supporting the development of therapies for rare diseases. Gene therapy technologies are gaining traction due to their potential to provide long-term or curative solutions compared to conventional enzyme replacement therapies. Increasing R&D investments by pharmaceutical companies and collaborations with research institutions are accelerating pipeline development, improving treatment outcomes, and expanding access to advanced therapies.

Growing Healthcare Infrastructure and Specialty Care Expansion
The expansion of specialty healthcare facilities and improved access to rare disease treatments are supporting market growth. According to the Organisation for Economic Co-operation and Development, global healthcare expenditure continues to rise, with many countries increasing investment in advanced treatment facilities and rare disease management programs. Hospitals and specialty clinics play a crucial role in administering complex therapies such as enzyme replacement therapy and gene therapy, driving demand across end-user segments. Additionally, the increasing adoption of homecare-based treatment approaches is improving patient convenience and long-term disease management.

Key Leaders Transforming the Hunter Syndrome Treatment Market
The key players in the hunter syndrome treatment market include Takeda Pharmaceutical Company Limited, GC Biopharma Corp., JCR Pharmaceuticals Co., Ltd., Denali Therapeutics Inc., and RegenxBio Inc., among others. These companies are focusing on product innovation, gene therapy advancements, and strategic collaborations to strengthen their market position.

• In March 2026, Denali Therapeutics Inc. received accelerated approval from the U.S. Food and Drug Administration for AVLAYAH™ (tividenofusp alfa-eknm) to treat Hunter syndrome (MPS II). The therapy is the first brain-penetrant biologic designed to cross the blood-brain barrier, marking the first major treatment advancement for the disease in nearly 20 years.
• In February 2026, REGENXBIO Inc. received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration for its RGX-121 gene therapy for Hunter syndrome (MPS II). The company plans to work with the FDA to address concerns and pursue a resubmission pathway for approval.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Treatment Type
• End-User
• Therapy Modality
• Regions Covered-
• North America
• Europe
• Asia-Pacific
• Rest of the World
• Competitive Landscape – Takeda Pharmaceutical Company Limited, GC Biopharma Corp., JCR Pharmaceuticals Co., Ltd., Denali Therapeutics Inc., RegenxBio Inc., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Hunter Syndrome Treatment Market Segmentation

By Treatment Type

• Enzyme Replacement Therapy (ERT)
• Gene Therapy
• Substrate Reduction Therapy (SRT)
• Supportive / Symptomatic Treatment

By End-User

• Hospitals
• Specialty Clinics
• Homecare Settings

By Therapy Modality

• Biologics
• Gene Therapy Platforms
• Small Molecule Therapies

Global Hunter Syndrome Treatment Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/hunter-syndrome-treatment-market